Topical Ketoprofen Versus Placebo in Patients With Ankle Sprain
Launched by AKDENIZ UNIVERSITY · Mar 19, 2015
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
Patients, 18-65 years old, presented with ankle sprain are enrolled into the study. Pain over 24 hours, pain intensity lower than 40 mm, allergy to the study drug, drug alcohol abuse and pregnancy or breastfeeding are the exclusion criteria. The study interventions are 2 gr of 2.5% ketoprofen gel versus placebo applied to the sprain area. The study drugs are identical in colour, form and smelling. After an eligible patient presented to the ED, the drug number from an opaque bag is determined by a nurse and then another nurse applies the study drug to the patient. Physicians, nurses and pati...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient presented with ankle sprain to the emergency department.
- • Patients between 18-65 years old.
- Exclusion Criteria:
- • Pain over 24 hours,
- • Pain intensity lower than 40 mm,
- • allergy to the study drug,
- • drug alcohol abuse
- • pregnancy or breastfeeding are the exclusion criteria.
About Akdeniz University
Akdeniz University is a leading academic institution located in Antalya, Turkey, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Akdeniz University leverages its extensive expertise and state-of-the-art facilities to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a diverse range of stakeholders, including healthcare professionals, researchers, and industry partners, to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Through its dedication to excellence in research, Akdeniz University plays a pivotal role in contributing to the development of new therapies and enhancing the understanding of various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denizli, , Turkey
Patients applied
Trial Officials
Mustafa Serinken, MD
Study Chair
Pamukkale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials